Rocio Garcia-Santibanez1, Matthew Burford2, Robert C Bucelli3. 1. Department of Neurology, Division of Neuromuscular Medicine, Emory University, Atlanta, GA, USA. 2. Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 3. Department of Neurology, Division of Neuromuscular Medicine, Washington University in St. Louis, 660 S Euclid Ave, Box 8111, St. Louis, MO, 63110, USA. bucellir@wustl.edu.
Abstract
PURPOSE OF REVIEW: This article provides an overview of recent advancements in the fields of hereditary motor neuropathies and ALS. RECENT FINDINGS: There has been a robust growth in our knowledge and understanding of hereditary and degenerative motor neuronopathies/neuropathies over the last decade. Many breakthroughs in the field of hereditary motor neuropathies (HMN) have been associated with identification and characterization of the genes and molecular mechanisms underlying these disorders. Similar recent breakthroughs on the genetic and molecular underpinnings of the degenerative motor neuronopathy, amyotrophic lateral sclerosis (ALS), have been accompanied by advancements in biomarker research and the development and FDA approval of novel therapies. There is a reasonable hope that the marked and continued growth in our understanding of the molecular pathophysiology of the HMNs will translate into novel therapeutic approaches in the decade to come. Such breakthroughs have already begun in ALS, where novel biomarkers and treatment strategies have translated into a new FDA-approved therapy with a number of promising agents in development and/or in definitive phase 2/3 trials.
PURPOSE OF REVIEW: This article provides an overview of recent advancements in the fields of hereditary motor neuropathies and ALS. RECENT FINDINGS: There has been a robust growth in our knowledge and understanding of hereditary and degenerative motor neuronopathies/neuropathies over the last decade. Many breakthroughs in the field of hereditary motor neuropathies (HMN) have been associated with identification and characterization of the genes and molecular mechanisms underlying these disorders. Similar recent breakthroughs on the genetic and molecular underpinnings of the degenerative motor neuronopathy, amyotrophic lateral sclerosis (ALS), have been accompanied by advancements in biomarker research and the development and FDA approval of novel therapies. There is a reasonable hope that the marked and continued growth in our understanding of the molecular pathophysiology of the HMNs will translate into novel therapeutic approaches in the decade to come. Such breakthroughs have already begun in ALS, where novel biomarkers and treatment strategies have translated into a new FDA-approved therapy with a number of promising agents in development and/or in definitive phase 2/3 trials.
Authors: Clotilde Lagier-Tourenne; Michael Baughn; Frank Rigo; Shuying Sun; Patrick Liu; Hai-Ri Li; Jie Jiang; Andrew T Watt; Seung Chun; Melanie Katz; Jinsong Qiu; Ying Sun; Shuo-Chien Ling; Qiang Zhu; Magdalini Polymenidou; Kevin Drenner; Jonathan W Artates; Melissa McAlonis-Downes; Sebastian Markmiller; Kasey R Hutt; Donald P Pizzo; Janet Cady; Matthew B Harms; Robert H Baloh; Scott R Vandenberg; Gene W Yeo; Xiang-Dong Fu; C Frank Bennett; Don W Cleveland; John Ravits Journal: Proc Natl Acad Sci U S A Date: 2013-10-29 Impact factor: 11.205
Authors: Emily Feneberg; Patrick Oeckl; Petra Steinacker; Federico Verde; Christian Barro; Philip Van Damme; Elizabeth Gray; Julian Grosskreutz; Claude Jardel; Jens Kuhle; Sonja Koerner; Foudil Lamari; Maria Del Mar Amador; Benjamin Mayer; Claudia Morelli; Petra Muckova; Susanne Petri; Koen Poesen; Joost Raaphorst; François Salachas; Vincenzo Silani; Beatrice Stubendorff; Martin R Turner; Marcel M Verbeek; Jochen H Weishaupt; Patrick Weydt; Albert C Ludolph; Markus Otto Journal: Neurology Date: 2017-12-06 Impact factor: 9.910
Authors: J G O'Rourke; L Bogdanik; A Yáñez; D Lall; A J Wolf; A K M G Muhammad; R Ho; S Carmona; J P Vit; J Zarrow; K J Kim; S Bell; M B Harms; T M Miller; C A Dangler; D M Underhill; H S Goodridge; C M Lutz; R H Baloh Journal: Science Date: 2016-03-18 Impact factor: 47.728
Authors: Mariely DeJesus-Hernandez; NiCole A Finch; Xue Wang; Tania F Gendron; Kevin F Bieniek; Michael G Heckman; Aliaksei Vasilevich; Melissa E Murray; Linda Rousseau; Rachael Weesner; Anthony Lucido; Meeia Parsons; Jeannie Chew; Keith A Josephs; Joseph E Parisi; David S Knopman; Ronald C Petersen; Bradley F Boeve; Neill R Graff-Radford; Jan de Boer; Yan W Asmann; Leonard Petrucelli; Kevin B Boylan; Dennis W Dickson; Marka van Blitterswijk; Rosa Rademakers Journal: Acta Neuropathol Date: 2017-05-15 Impact factor: 17.088